

Which type of drugs are included in Cortellis?


Cortellis Competitive Intelligence gathers data from hundreds of scientific and commercial sources to provide the information you need when evaluating drugs in your field of research. All therapy areas are included as well as rare diseases.

Cortellis focuses on prescription drugs -patent protected- and developed for human use since 1990s. Coverage starts in discovery phase and continues through preclinical, clinical trials, approval process until the drug is launched or discontinued.

Small molecules, biologics, drug combinations, biosimilars, salts and new versions of existing drugs with an element of innovation -like a new formulation- are also included in Cortellis.

The following are examples of types of drugs you will find and how to search for them.

1. Type the name of the drug in the main Search.



2. Original and related drugs will be listed in the results table where indexing information is available to help you quickly identify mechanism of action, indication, company, and other details for each drug.

Results	Per page: 25	Sort by: Last Change Date	Most Recent	Order Columns	View
Drug Name	Active Companies	Active Indications	Target-based Actions	Highest Status	Regulatory Designations
sofosbuvir	Biotoscana International; Gilead Sciences Inc	Hepatitis C virus infection	Hepatitis C virus NS5B polymerase inhibitor	Launched (Hepatitis C virus infection - US - Dec-2013)	Breakthrough Therapy; Fast Track; Orphan Drug; Paediatric Investigation Plan
sofosbuvir + ledipasvir (fixed- combination/oral, HCV/HBV), Gilead	Biotoscana International; Gilead Sciences Inc	Hepatitis B virus infection; Hepatitis C virus infection	Hepa polyr Hepa inhib		

Drug combinations are included in Cortellis as separate records.

Results		Per page: 25	Sort by: Relevance	Order Columns	View
Drug Name	Active Companies	Active Indications	Target-based Actions	Highest Status	Regulatory Designations
lacosamide	Daiichi Sankyo Co Ltd; NewBridge Pharmaceuticals Ltd; Orient Europharma; UCB Pharma GmbH; UCB SA	Epilepsy; Partial seizure; Tonic clonic epilepsy	Dihydropyrimidinas protein 2 modulator; channel modulator		
lacosamide (oral extended release, epilepsy), Adamas	Adamas Pharmaceuticals Inc	Epilepsy	Dihydropyrimidinase related protein 2 modulator; Sodium channel modulator	Phase 1 Clinical	

New formulations can also be found by searching the original drug name.

Results	Per page: 25	Sort by: Last Change Date	Most Recent	Order Columns	View
Drug Name	Active Companies	Active Indications	Target-based Actions	Highest Status	Regulatory Designations
bevacizumab	Chugai Pharmaceutical Co Ltd; F Hoffmann-La Roche AG; Genentech Inc; Roche Holding AG	Cerebral edema; Colorectal tumor; Endometrioid carcinoma; Ewing sarcoma; Fallopian tube cancer;	VEGF ligand inhibitor		
bevacizumab biosimilar, Mylan/Biocon	Biocon Ltd; Mylan NV	Brain tumor; Cancer; Glioblastoma; Metastatic colorectal cancer; Metastatic renal cell carcinoma; Non-	VEGF ligand inhibitor		

Click a drug name to read expert insights.

For more information contact Customer Service at LSH.support@clarivate.com.